Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Thrombosis and Haemostasis

• Publication date

  2016-09-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1160/TH16-05-0403PMID 27538358
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study

  2016cited by this paper
• Cardiovascular, Bleeding, and Mortality Risks in Elderly Medicare Patients Treated With Dabigatran or Warfarin for Nonvalvular Atrial Fibrillation

  2015influential reference
• Safety and effectiveness of dabigatran and warfarin in routine care of patients with atrial fibrillation

  2015cited by this paper
• Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study

  2015cited by this paper
• XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation

  2015influential reference
• Ischemic Stroke and Intracranial Hemorrhage With Aspirin, Dabigatran, and Warfarin: Impact of Quality of Anticoagulation Control

  2015cited by this paper
• 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society.

  2014cited by this paper
• Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials.

  2014influential reference
• 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society.

  2014cited by this paper
• Vitamin K antagonists in heart disease: Current status and perspectives (Section III)

  2013cited by this paper
• Dabigatran and postmarketing reports of bleeding.

  2013influential reference
• Apixaban versus Warfarin in Patients with Atrial Fibrillation

  2012cited by this paper
• An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation

  2012cited by this paper
• Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.

  2012cited by this paper
• Apixaban versus warfarin in patients with atrial fibrillation.

  2011cited by this paper
• An automated database case definition for serious bleeding related to oral anticoagulant use

  2011cited by this paper
• Propensity score methods for creating covariate balance in observational studies

  2011cited by this paper
• An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies

  2011influential reference
• Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.

  2011cited by this paper
• [Propensity score methods for creating covariate balance in observational studies].

  2011cited by this paper
• Underuse of oral anticoagulants in atrial fibrillation: a systematic review.

  2010cited by this paper
• Dabigatran versus warfarin in patients with atrial fibrillation.

  2009influential reference
• Adjusted-dose warfarin versus aspirin for preventing stroke in patients with atrial fibrillation.

  2007cited by this paper
• Stroke in atrial fibrillation: Update on pathophysiology, new antithrombotic therapies, and evolution of procedures and devices

  2007cited by this paper
• Too much ado about propensity score models? Comparing methods of propensity score matching.

  2006influential reference
• A Proportional Hazards Model for the Subdistribution of a Competing Risk

  1999cited by this paper
• Atrial fibrillation: a major contributor to stroke in the elderly. The Framingham Study.

  1987cited by this paper
• Statistical Primer for Cardiovascular Research Introduction to the Analysis of Survival Data in the Presence of Competing Risks

  year unknowncited by this paper

• Risk of thromboembolic events and bleeding in patients with nonvalvular atrial fibrillation after switching from warfarin to direct oral anticoagulant

  2026cites this paper
• Impact of Islet Transplantation on Diabetes Complications and Mortality in Patients Living With Type 1 Diabetes

  2025cites this paper
• Beyond Routine Monitoring: A Comprehensive Review of Direct Oral Anticoagulants and the Role of Coagulation Profiles in Their Management

  2025cites this paper
• Hemorrhage Risk Associated with Anticoagulant and Antiplatelet Drug Combinations: Insights from the USFDA Adverse Event Reporting System

  2025influential citation
• Malignancy-Associated Pulmonary Embolism: Mortality, Recurrence, and Bleeding Risks

  2025cites this paper
• Comparative Safety of Tenecteplase and Alteplase in Direct Oral Anticoagulant‐Pretreated Patients With Acute Ischemic Stroke

  2025cites this paper
• Safety and Effectiveness of Oral Anticoagulants in Atrial Fibrillation: Real-World Insights Using Natural Language Processing and Machine Learning

  2024cites this paper
• Oral anticoagulant treatment in atrial fibrillation: The AFIRMA real-world study using natural language processing and machine learning.

  2024cites this paper
• Treatment patterns and outcomes among adults with immune thrombocytopenia receiving pharmaceutical second-line therapies: a retrospective cohort study using administrative claims data

  2024cites this paper
• Tratamiento anticoagulante oral en la fibrilación auricular: AFIRMA, el estudio de vida real realizado mediante procesamiento de lenguaje natural y aprendizaje automático

  2024cites this paper
• Cost‐Effectiveness and Budget Impact Analysis of Apixaban and Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Non‐Valvular Atrial Fibrillation (NVAF) in Iran

  2024influential citation
• Advice to the FDA to Improve Its Proposed Guidelines to Rationalize Clinical Trials by Restricting Placebo Control, Preventing Low-Powered Studies, and Disallowing Studies Where Bioavailability Is Not Proven

  2024cites this paper
• Increased major bleeding incidence in atrial fibrillation patients with apixaban: a review of Japanese post-marketing surveillance studies of direct oral anticoagulants

  2023cites this paper
• Identifying treatment heterogeneity in atrial fibrillation using a novel causal machine learning method

  2023cites this paper
• Gastrointestinal bleeding with direct oral anticoagulants in patients with atrial fibrillation and anaemia.

  2023cites this paper
• Healthcare resources and costs associated with nonvalvular atrial fibrillation in Spain: apixaban versus acenocoumarol

  2023cites this paper
• Real world evidence: Perspectives from a European Society of Cardiology Cardiovascular Round Table with contribution from the European Medicines Agency.

  2023cites this paper
• Utilization outcomes of direct oral anticoagulants in Medicare patients.

  2023cites this paper
• Use of Bisphosphonates and the Risk of Skin Ulcer: A National Cohort Study Using Data from the French Health Care Claims Database

  2023cites this paper
• Large-scale Empirical Identification of Candidate Comparators for Pharmacoepidemiological Studies

  2023cites this paper
• Anticoagulation in atrial fibrillation. A large real-world update.

  2023cites this paper
• Effectiveness and Safety of Apixaban in over 3.9 Million People with Atrial Fibrillation: A Systematic Review and Meta-Analysis

  2022cites this paper
• Orthopedic Surgery Referral Pattern Analysis per Demographic Factors Among Patients Diagnosed With Severe Peripheral Artery Disease in Terms of Partial or Total Limb Amputation

  2022cites this paper
• Assessing Medicines for Use in the Geriatric Population

  2022cites this paper
• Understanding variation in the results of real-world evidence studies that address the same question.

  2022cites this paper
• A Comparative Assessment Study of Known Small-molecule GPVI Modulators.

  2022cites this paper
• Comparative Effectiveness of Ticagrelor, Prasugrel, and Clopidogrel for Secondary Prophylaxis in Acute Coronary Syndrome: A Propensity Score‐Matched Cohort Study

  2022cites this paper
• Concurrent use of statins decreases major bleeding and intracerebral hemorrhage in non-valvular atrial fibrillation patients taking direct oral anticoagulants—A nationwide cohort study

  2022cites this paper
• Retrospective real-world meta-analysis of high-risk major bleeding as a primary safety outcome in cancer patients receiving therapeutic anticoagulation

  2022cites this paper
• Adverse 30-Day Clinical Outcomes and Long-Term Mortality Among Patients With Preprocedural Atrial Fibrillation Undergoing Percutaneous Coronary Intervention.

  2022cites this paper
• Comparative Risk of Hospitalized Bleeding of P2Y12 Inhibitors for Secondary Prophylaxis in Acute Coronary Syndrome After Percutaneous Coronary Intervention

  2022cites this paper
• Major bleeding in users of direct oral anticoagulants in atrial fibrillation: A pooled analysis of results from multiple population‐based cohort studies

  2021cites this paper
• Comprehensive Exploration of Medications That Affect the Bleeding Risk of Oral Anticoagulant Users.

  2021cites this paper
• Successful emergency surgery in a patient on dabigatran, after reversing the anticoagulation effect using Idarucizumab – A case report

  2021cites this paper
• Evidence and uncertainties in the management of atrial fibrillation in older persons.

  2021cites this paper
• Antithrombotic Management and Long-Term Outcomes of Patients with Atrial Fibrillation. Insights from CRAFT Trial

  2021cites this paper
• Comparative effectiveness and safety of direct acting oral anticoagulants in nonvalvular atrial fibrillation for stroke prevention: a systematic review and meta-analysis

  2021cites this paper
• Direct comparison of non-vitamin K antagonist oral anticoagulant versus warfarin for stroke prevention in non-valvular atrial fibrillation: a systematic review and meta-analysis of real-world evidences

  2021cites this paper
• Cost-Effectiveness of Direct Non-Vitamin K Oral Anticoagulants Versus Vitamin K Antagonists for the Management of Patients with Non-Valvular Atrial Fibrillation Based on Available “Real-World” Evidence: The Italian National Health System Perspective

  2021cites this paper
• Comparative Effectiveness and Safety of Non–Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients

  2021cites this paper
• Factors Influencing the Selection of Non-Vitamin K Antagonist Oral Anticoagulants for Stroke Prevention in Patients With Non-Valvular Atrial Fibrillation

  2021cites this paper
• The Risk of Falling and Consequences of Falling in Patients with Atrial Fibrillation Receiving Different Types of Anticoagulant

  2021cites this paper
• The Effect of Rivaroxaban on CYP4F2 and Transcription Factors’ Activity in HUVECs

  2021cites this paper
• Effectiveness and Safety of Dabigatran Compared to Vitamin K Antagonists in Non-Asian Patients with Atrial Fibrillation: A Systematic Review and Meta-Analysis

  2021cites this paper
• Use of NOACS in high-risk patients with atrial fibrillation in Saudi Arabia: Perspectives on improving patient care

  2021cites this paper
• Critical appraisal and issues regarding generalisability of comparative effectiveness studies of NOACs in atrial fibrillation and their relation to clinical trial data: a systematic review

  2021cites this paper
• Comparative Risk Assessment of Severe Uterine Bleeding Following Exposure to Direct Oral Anticoagulants: A Network Study Across Four Observational Databases in the USA

  2021cites this paper
• Effectiveness and safety of dabigatran compared to vitamin K antagonists in patients with atrial �brillation: a systematic review and metanalysis.

  2021cites this paper
• Geriatric conditions do not predict stroke or bleeding in long‐term care residents with atrial fibrillation

  2021cites this paper
• Comparative Safety and Effectiveness of Apixaban vs. Warfarin in Oral Anticoagulant-Naïve Japanese Patients With Non-Valvular Atrial Fibrillation　- A Retrospective Chart Review Study.

  2021cites this paper
• [Treatment strategies for patients with atrial fibrillation and chronic heart failure].

  2021cites this paper
• Real-world safety and efficacy of direct oral anticoagulants in atrial fibrillation: a network metanalysis on 605,771 patients.

  2021cites this paper
• Novel bleeding prediction model in atrial fibrillation patients on new oral anticoagulants

  2021cites this paper
• The development and validation of a multivariable model to predict the bleeding risk score for patients with non-valvular atrial fibrillation using direct oral anticoagulants in the Arab population

  2021cites this paper
• Effectiveness and safety of non‐vitamin K antagonist oral anticoagulants in patients with non‐valvular atrial fibrillation: A nationwide, population‐based study in Korea

  2021cites this paper
• Comparison of the Safety and Effectiveness of Four Direct Oral Anticoagulants in Japanese Patients with Nonvalvular Atrial Fibrillation Using Real-World Data.

  2021cites this paper
• Association of Direct Oral Anticoagulants (DOACs) and Warfarin With Haemorrhagic Risk by Applying Correspondence Analysis to Data From the Italian Pharmacovigilance Database – A Case Study

  2021cites this paper
• Management of cardiovascular complications of bruton tyrosine kinase inhibitors

  2021cites this paper
• Major gastrointestinal bleeding risk with direct oral anticoagulants: Does type and dose matter? – A systematic review and network meta-analysis

  2021cites this paper
• Analysis of the Risks of Stroke, Bleeding and Death in Elderly Patients with Nonvalvular Atrial Fibrillation who Received Various Oral Anticoagulants under the Program Medicare, USA

  2020cites this paper
• Current aspects of TIA management.

  2020cites this paper
• A Systematic Review of Network Meta-Analyses and Real-World Evidence Comparing Apixaban and Rivaroxaban in Nonvalvular Atrial Fibrillation

  2020cites this paper
• Real‐world direct oral anticoagulant experience in atrial fibrillation: falls risk and low dose anticoagulation are predictive of both bleeding and stroke risk

  2020cites this paper
• COMPARATIVE CHARACTERISTICS OF ANTICOAGULANTS AT ATRIAL FIBRILLATION IN COMORBID PATIENTS

  2020cites this paper
• Arrythmias in Chronic Kidney Disease: Working Towards a Clinical Approach in Atrial Fibrillation

  2020cites this paper
• Direct Oral Anticoagulants: Drug Selection by Means of the SOJA Method

  2020cites this paper
• Effectiveness and safety among direct oral anticoagulants in nonvalvular atrial fibrillation: A multi‐database cohort study with meta‐analysis

  2020cites this paper
• Bleeding risk after percutaneous breast needle biopsy in patients on anticoagulation therapy.

  2020cites this paper
• Comparative Clinical Outcomes of Edoxaban in Adults With Nonvalvular Atrial Fibrillation.

  2020cites this paper
• Rivaroxaban versus warfarin in Chinese elder diabetic patients with non-valvular atrial fibrillation: A retrospective study on the effectiveness and associated risks (EAR) analysis

  2020cites this paper
• Real-world cost-effectiveness of rivaroxaban and apixaban vs VKA in stroke prevention in non-valvular atrial fibrillation in the UK

  2020cites this paper
• Anticoagulation in Italian patients with venous thromboembolism and thrombophilic alterations: findings from START2 register study.

  2020cites this paper
• Real-world on-treatment and initial treatment absolute risk differences for dabigatran vs warfarin in older US adults.

  2020cites this paper
• Effectiveness and safety of dabigatran in Latin American patients with atrial fibrillation: Two years follow up results from GLORIA-AF registry

  2020cites this paper
• Oral anticoagulants in the prevention of thromboembolic complications in cardiac patients: analysis of use in the Russian Federation

  2020cites this paper
• Reweighting Oranges to Apples: Transported RE-LY Trial vs Non-experimental Effect Estimates of Anticoagulation in Atrial Fibrillation.

  2020cites this paper
• Оральные антикоагулянты в профилактике тромоэмболических осложнений у кардиологических пациентов: анализ применения в Российской Федерации

  2020cites this paper
• Incidence Rates of Bleeding and Emergency Surgery Due to Trauma or Fracture Among Japanese Patients with Non-valvular Atrial Fibrillation Receiving Oral Anticoagulation Therapy

  2020cites this paper
• Comparative Safety and Effectiveness of Oral Anticoagulants in Nonvalvular Atrial Fibrillation

  2020cites this paper
• Comparing risk of major bleeding between users of different oral anticoagulants in patients with nonvalvular atrial fibrillation

  2020cites this paper
• Evaluation of the Incremental Healthcare Economic Burden of Patients with Atrial Fibrillation Treated with Direct-Acting Oral Anticoagulants and Hospitalized for Major Bleeds in the USA

  2020cites this paper
• Reweighting Oranges to Apples: Transported RE-LY Trial Versus Nonexperimental Effect Estimates of Anticoagulation in Atrial Fibrillation.

  2020cites this paper
• Safety and effectiveness of non-vitamin K oral anticoagulants versus warfarin in real-world patients with non-valvular atrial fibrillation: a retrospective analysis of contemporary Japanese administrative claims data

  2020cites this paper
• Rates, management and outcome of bleeding complications during edoxaban therapy in daily care - results from the DRESDEN NOAC REGISTRY.

  2020cites this paper
• Risk of Major Gastrointestinal Bleeding With New vs Conventional Oral Anticoagulants-a Systematic Review and Meta-analysis.

  2020cites this paper
• Practice-derived data on non-vitamin K antagonist oral anticoagulant therapy to complement observations from randomized trials

  2020cites this paper
• Treatment strategies for patients with atrial fibrillation and anticoagulant-associated intracranial hemorrhage: an overview of the pharmacotherapy

  2020cites this paper
• Comparative effectiveness and safety of oral anticoagulants for atrial fibrillation: A retrospective cohort study.

  2020cites this paper
• Effectiveness and Safety of Direct Oral Anticoagulants in Relation to Temporal Changes in Their Use

  2020cites this paper
• Methodological education in response to the quality of COVID-19 publications

  2020cites this paper
• Impact of Liver Disease on Oral Anticoagulant Prescription and Major Adverse Events in Patients with Atrial Fibrillation.

  2020cites this paper
• Évènements hémorragiques dans une population gériatrique nouvellement traitée par anticoagulation orale pour fibrillation atriale

  2020cites this paper
• Real‐world data on the incidence, mortality, and cost of ischaemic stroke and major bleeding events among non‐valvular atrial fibrillation patients in England

  2020cites this paper
• Real-world cost-effectiveness of rivaroxaban compared with vitamin K antagonists in the context of stroke prevention in atrial fibrillation in France

  2020influential citation
• Bleeding Risk in Nonvalvular Atrial Fibrillation Patients Receiving Direct Oral Anticoagulants and Warfarin: A Systematic Review and Meta-Analysis of Observational Studies

  2020cites this paper
• Direct comparisons of effectiveness and safety of treatment with Apixaban, Dabigatran and rivaroxaban in atrial fibrillation.

  2019cites this paper
• Equivalent inpatient mortality among direct-acting oral anticoagulant and warfarin users presenting with major hemorrhage.

  2019cites this paper
• Safety and Effectiveness of Dabigatran and Other Direct Oral Anticoagulants Compared With Warfarin in Patients With Atrial Fibrillation

  2019cites this paper
• Practical use of Direct Oral Anti Coagulants (DOACs) in the older persons with atrial fibrillation.

  2019cites this paper
• Non-vitamin K oral anticoagulant use in the elderly: a prospective real-world study – data from the REGIstry of patients on Non-vitamin K oral Anticoagulants (REGINA)

  2019cites this paper